Liu C, Huang J, Chang H, Chen C, Tsai Y, Chen W
J Pathol. 2025; 265(3):289-301.
PMID: 39844613
PMC: 11794964.
DOI: 10.1002/path.6384.
Zhou C, Lin Z, Li X, Zhang D, Song P
Front Vet Sci. 2023; 10:1129756.
PMID: 37077947
PMC: 10108679.
DOI: 10.3389/fvets.2023.1129756.
Tyagi A, Kaushal K, Chandrasekaran A, Sarodaya N, Das S, Park C
Theranostics. 2022; 12(13):5949-5970.
PMID: 35966591
PMC: 9373805.
DOI: 10.7150/thno.72826.
Xu J, Gewirtz D
Biomolecules. 2022; 12(3).
PMID: 35327655
PMC: 8946631.
DOI: 10.3390/biom12030463.
Sousa D, Lima R, Lopes-Rodrigues V, Gonzalez E, Royo F, Xavier C
Cells. 2021; 10(11).
PMID: 34831110
PMC: 8616370.
DOI: 10.3390/cells10112886.
RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway.
Shriwas O, Arya R, Mohanty S, Mohapatra P, Kumar S, Rath R
Br J Cancer. 2021; 124(12):2004-2016.
PMID: 33762722
PMC: 8184829.
DOI: 10.1038/s41416-021-01336-7.
Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E, Kim J, Kim H, Yoon H
Int J Mol Sci. 2020; 21(20).
PMID: 33076245
PMC: 7589258.
DOI: 10.3390/ijms21207613.
Membrane Transporters and Channels in Melanoma.
Bohme I, Schonherr R, Eberle J, Bosserhoff A
Rev Physiol Biochem Pharmacol. 2020; 181:269-374.
PMID: 32737752
DOI: 10.1007/112_2020_17.
TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y, Liu Y, Liu T, Meng Q, Lu H, Liu W
Cell Commun Signal. 2018; 16(1):43.
PMID: 30064446
PMC: 6069800.
DOI: 10.1186/s12964-018-0254-x.
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J, Meng Q, Zhao Y, Chen X, Cai L
BMC Cancer. 2016; 16:470.
PMID: 27411790
PMC: 4944258.
DOI: 10.1186/s12885-016-2527-3.
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y, Choi Y, Kim K, Shin D
Oncotarget. 2016; 7(28):43315-43323.
PMID: 27270313
PMC: 5190025.
DOI: 10.18632/oncotarget.9703.
Heterogeneous response of different tumor cell lines to methotrexate-coupled nanoparticles in presence of hyperthermia.
Stapf M, Pompner N, Teichgraber U, Hilger I
Int J Nanomedicine. 2016; 11:485-500.
PMID: 26893557
PMC: 4745830.
DOI: 10.2147/IJN.S94384.
Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells.
Zhang L, Yang A, Wang M, Liu W, Wang C, Xie X
Apoptosis. 2016; 21(4):473-88.
PMID: 26767845
PMC: 4915730.
DOI: 10.1007/s10495-016-1214-9.
Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation.
Ma J, Yang J, Wang C, Zhang N, Dong Y, Wang C
Biomed Res Int. 2015; 2014:107671.
PMID: 25580427
PMC: 4279181.
DOI: 10.1155/2014/107671.
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.
Hall M, Telma K, Chang K, Lee T, Madigan J, Lloyd J
Cancer Res. 2014; 74(14):3913-22.
PMID: 24812268
PMC: 4153432.
DOI: 10.1158/0008-5472.CAN-14-0247.
Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306.
Fung K, Tepede A, Pluchino K, Pouliot L, Pixley J, Hall M
Mol Pharm. 2014; 11(8):2692-702.
PMID: 24800945
PMC: 4137994.
DOI: 10.1021/mp500114e.
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
McDermott M, Eustace A, Busschots S, Breen L, Crown J, Clynes M
Front Oncol. 2014; 4:40.
PMID: 24639951
PMC: 3944788.
DOI: 10.3389/fonc.2014.00040.
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells.
Schultz M, Swindall A, Wright J, Sztul E, Landen C, Bellis S
J Ovarian Res. 2013; 6(1):25.
PMID: 23578204
PMC: 3637436.
DOI: 10.1186/1757-2215-6-25.
Detection of glycomic alterations induced by overexpression of p-glycoprotein on the surfaces of L1210 cells using sialic acid binding lectins.
Bubencikova T, Cholujova D, Messingerova L, Mislovicova D, Seres M, Breier A
Int J Mol Sci. 2012; 13(11):15177-92.
PMID: 23203118
PMC: 3509634.
DOI: 10.3390/ijms131115177.
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.
Pouliot L, Shen D, Suzuki T, Hall M, Gottesman M
Exp Cell Res. 2012; 319(4):566-74.
PMID: 23137650
PMC: 3563763.
DOI: 10.1016/j.yexcr.2012.10.012.